Success in gene therapy relies on the ability to safely and precisely deliver a genetic payload to the intended target cells. This presentation describes a novel approach that combines next-gen library synthesis, next-gen sequencing, artificial intelligence, and novel fixed bed bioreactor technology to accelerate the production of improved indication-specific AAV capsids, to deliver therapeutic transgenes. The speaker will share their strategy for efficiently scaling up high throughput AAV library production, including results from recent studies using the Corning® Ascent™ fixed bed bioreactor technology.